Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Current Deferred Revenue (2017 - 2025)

Assembly Biosciences (ASMB) has 9 years of Current Deferred Revenue data on record, last reported at $42.4 million in Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 34.96% year-over-year to $42.4 million; the TTM value through Sep 2025 reached $42.4 million, down 34.96%, while the annual FY2024 figure was $37.6 million, 56.4% down from the prior year.
  • Current Deferred Revenue reached $42.4 million in Q3 2025 per ASMB's latest filing, up from $40.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $86.3 million in Q4 2023 and bottomed at $2.7 million in Q3 2021.
  • Average Current Deferred Revenue over 5 years is $31.2 million, with a median of $33.1 million recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: plummeted 75.06% in 2021, then skyrocketed 3057.48% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $2.7 million in 2021, then changed by 0.0% to $2.7 million in 2022, then surged by 3057.48% to $86.3 million in 2023, then plummeted by 56.4% to $37.6 million in 2024, then grew by 12.6% to $42.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $42.4 million in Q3 2025, $40.9 million in Q2 2025, and $40.8 million in Q1 2025.